ASX:EMDPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Emyria Ltd
$0.043
$0.002 (4.44%)
Day Range
$0.043 – $0.045
52 Week Range
$0.023 – $0.078
Volume
1.11M
Avg Volume (10D)
1.37M
Market Cap
$34.68M
Price Chart
Market Statistics
Open$0.045
Previous Close$0.045
Day High$0.045
Day Low$0.043
52 Week High$0.078
52 Week Low$0.023
Valuation
Market Cap34.68M
Shares Outstanding806.56M
Price to Book2.99
Trading Activity
Volume1.11M
Value Traded47.99K
Bid$0.042 × 649,274
Ask$0.043 × 59,333
Performance
1 Day-4.26%
5 Day0.00%
13 Week-6.25%
52 Week87.50%
YTD-23.73%
Technical Indicators
RSI (14)46.76
50-Day SMA$0.046
200-Day SMA$0.053
Latest News
Biotechnology
Emyria Poised for Operational Boost as TGA Broadens Psych-Therapy Prescriber Access
Emyria is set to accelerate recruitment as TGA broadens Authorised Prescriber roles for psychedelic therapy, boosting Empax network expansion into H2 2026.
Biotechnology
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria unveils Empax global partnership platform to link international sponsors with its clinical delivery network; Psyence signs for Phase IIb trial.
Biotechnology
Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement
Emyria expands Medibank funding to Victoria, unlocking Empax TRD/PTSD care at Avive Mornington Peninsula; nationwide rollout underway.
Biotechnology
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.